Clinical Trial Update: JAB-3068 Activity in Adult Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/Phase 2 trial update for JAB-3068 in adults with advanced solid tumors, including Esophageal Squamous Cell Carcinoma, Non-Small Cell Lung Ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• JAB-3068 (SHP2 inhibitor)

Snippet

Sponsor: Jacobio Pharmaceuticals Co., Ltd. | Conditions: Advanced Solid Tumor, Esophageal Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED